Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of sacituzumab govitecan combinations as first-line treatment for advanced or metastatic NSCLC without actionable genomic alterations
2024-513225-23-00Phase 2Authorised
- Sponsor
- Gilead Sciences
- Start
- Apr 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 12
01
Overview
Phase 2, open-label trial of sacituzumab govitecan, pembrolizumab, carboplatin and cisplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Gilead Sciences. Primary endpoints: Objective response rate and Incidence of dose-limiting toxicities. Planned start Apr 2022; status: authorised.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-513225-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513225-23-00.